Bill Gerhart

Bill Gerhart has more than 20 years of experience building high-performance execution teams to develop new therapeutics for serious diseases. Prior to joining Kinevant in 2021, he was the CEO of Respivant/Patara Pharma, Elevation Pharma, and Mpex Pharma which focused on developing new medicines for pulmonary fibrosis, chronic obstructive pulmonary disease, and cystic fibrosis, respectively. In addition to his biotech activities, Bill serves as the Vice Chair of Sanford Burnham Prebys Institute’s Board of Trustees, a non-profit medical research institute focused on basic and translational research in cancer, neurodegeneration, infectious, and inflammatory diseases.

Bill earned a BA from Baylor University and an MBA from Harvard Business School.